Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced positive results from the first dosing group of an ongoing drug-drug interaction and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE